Form 4: Corcept Therapeutics Officer Reports Stock Transfers

Sean Maduck, President of Corcept Endocrinology, reported several non-cash transactions involving common stock, primarily transfers between trusts and LLCs.

Summary

• Sean Maduck, an officer (President, Corcept Endocrinology) of CORCEPT THERAPEUTICS INC (CORT), filed a Form 4.
• Reported transactions on January 8, 2026, involved common stock with a price of $0.00 per share.
• Disposed of 20,570 shares indirectly held by Sean and Molly Maduck Living Trust (Transaction Code G).
• Acquired 20,570 shares indirectly held by MMM 2025, LLC (Transaction Code J).
• Disposed of 34,000 shares indirectly held by Sean and Molly Maduck Living Trust (Transaction Code G).
• Acquired 34,000 shares indirectly held by SNM 2026 Grantor Retained Annuity Trust (Transaction Code J).
• Beneficial ownership following transactions includes 39,147 shares indirectly through Sean and Molly Maduck Living Trust, 20,570 shares indirectly through MMM 2025, LLC, and 34,000 shares indirectly through SNM 2026 Grantor Retained Annuity Trust.
• Directly owns 8,179 shares, which include 266, 888, 228, and 205 unvested restricted stock awards granted on March 3, 2025, June 2, 2025, September 2, 2025, and December 1, 2025, respectively, with 100% vesting one year from the grant date.
• Indirectly owns 40,000 shares through SNM 2025 Grantor Retained Annuity Trust and 10,000 shares through Duckhill Capital, LLC, disclaiming beneficial ownership except to the extent of pecuniary interest.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports internal transfers of shares by an officer, which are routine compliance disclosures and do not reflect on the company's operational performance or strategic direction.

Positives

• Officer Sean Maduck maintains significant beneficial ownership in Corcept Therapeutics common stock, aligning his interests with shareholders.

Negatives

• No direct negatives for the company's operational or financial performance are indicated in this compliance filing.

Risks

• No specific company risks are disclosed in this Form 4 filing.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• No notable quotes or paraphrased statements from company management are included in this Form 4 filing.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insiders, providing transparency into their holdings and transactions. These specific transactions appear to be internal transfers between various trusts and LLCs controlled by the reporting person, rather than open market sales or purchases, which is common for estate planning or asset management purposes.

Comparison to Industry Standards

• This Form 4 filing, detailing insider transactions, does not provide data suitable for comparison to industry-specific operational or financial benchmarks.

Related Party Transactions

• Transactions involve transfers of common stock between the reporting person and entities where the reporting person is a co-trustee, member/manager, or trustee (Sean and Molly Maduck Living Trust, MMM 2025, LLC, SNM 2026 Grantor Retained Annuity Trust, SNM 2025 Grantor Retained Annuity Trust, and Duckhill Capital, LLC).

Stakeholder Impact

• Shareholders: Provides transparency regarding an officer's beneficial ownership structure, but the internal transfers are unlikely to directly impact share price or company operations.
• Employees, Customers, Suppliers, Creditors: No direct impact indicated by this filing.

Next Steps

• Unvested restricted stock awards will vest on the one-year anniversary of their respective grant dates, provided the reporting person satisfies certain requirements.

Key Dates

Recommendation

This Form 4 primarily details internal transfers of shares by an officer between various trusts and LLCs, rather than open market purchases or sales. While it demonstrates continued significant insider ownership, which can be a positive signal of alignment, it does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as it maintains transparency without indicating a fundamental shift.

Keywords

CORCEPT THERAPEUTICS, CORT, Sean Maduck, Form 4, Insider Transaction, Beneficial Ownership, Stock Transfer, Restricted Stock Awards, Trust, LLC